000155571 001__ 155571
000155571 005__ 20240320115511.0
000155571 0247_ $$2ISSN$$a0003-9373
000155571 0247_ $$2doi$$a10.1007/s00406-021-01268-6
000155571 0247_ $$2pmid$$apmid:33942148
000155571 0247_ $$2pmc$$apmc:PMC8092366
000155571 0247_ $$2ISSN$$a0175-758X
000155571 0247_ $$2ISSN$$a0940-1334
000155571 0247_ $$2ISSN$$a1433-8491
000155571 0247_ $$2altmetric$$aaltmetric:105292377
000155571 037__ $$aDZNE-2021-00749
000155571 041__ $$aEnglish
000155571 082__ $$a610
000155571 1001_ $$aBelz, Michael$$b0
000155571 245__ $$aEvolution of psychosocial burden and psychiatric symptoms in patients with psychiatric disorders during the Covid-19 pandemic.
000155571 260__ $$aHeidelberg$$bSpringer$$c2022
000155571 3367_ $$2DRIVER$$aarticle
000155571 3367_ $$2DataCite$$aOutput Types/Journal article
000155571 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655125926_6959
000155571 3367_ $$2BibTeX$$aARTICLE
000155571 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155571 3367_ $$00$$2EndNote$$aJournal Article
000155571 500__ $$a(CC BY)
000155571 520__ $$aThe Covid-19 pandemic highly impacts mental health worldwide. Patients with psychiatric disorders are a vulnerable risk population for worsening of their condition and relapse of symptoms. This study investigates the pandemic-related course of psychosocial burden in patients with pre-existing mental disorders. With the newly developed Goettingen psychosocial Burden and Symptom Inventory (Goe-BSI) psychosocial burden has been traced retrospectively (1) before the pandemic (beginning of 2020), (2) at its beginning under maximum lockdown conditions (March 2020), and (3) for the current state after maximum lockdown conditions (April/May 2020). The Goe-BSI also integrates the Adjustment Disorder New Module (ADNM-20), assesses general psychiatric symptoms, and resilience. A total of 213 patients covering all major psychiatric disorders (ICD-10 F0-F9) were interviewed once in the time range from April, 24th until May 11th, 2020. Across all diagnoses patients exhibited a distinct pattern with an initial rise followed by a decline of psychosocial burden (p < 0.001, partial η2 = 0.09; Bonferroni-corrected pairwise comparisons between all three time-points: p < 0.05 to 0.001). Female gender and high ADNM-20 scores were identified as risk factors for higher levels and an unfavorable course of psychosocial burden over time. Most psychiatric symptoms remained unchanged. Trajectories of psychosocial burden vary in parallel to local lockdown restrictions and seem to reflect an adaptive stress response. For female patients with pre-existing mental disorders and patients with high-stress responses, timely and specific treatment should be scheduled. With the continuation of the pandemic, monitoring of long-term effects is of major importance, especially when long incubation times for the development of mental health issues are considered.
000155571 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000155571 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000155571 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000155571 650_7 $$2Other$$aAdjustment disorder
000155571 650_7 $$2Other$$aCoronavirus
000155571 650_7 $$2Other$$aMental health
000155571 650_7 $$2Other$$aPsychosocial stress
000155571 650_7 $$2Other$$aSARS-CoV-2
000155571 650_2 $$2MeSH$$aCOVID-19: epidemiology
000155571 650_2 $$2MeSH$$aCOVID-19: psychology
000155571 650_2 $$2MeSH$$aCost of Illness
000155571 650_2 $$2MeSH$$aFemale
000155571 650_2 $$2MeSH$$aHumans
000155571 650_2 $$2MeSH$$aMental Disorders: epidemiology
000155571 650_2 $$2MeSH$$aMental Disorders: psychology
000155571 650_2 $$2MeSH$$aPandemics
000155571 650_2 $$2MeSH$$aRetrospective Studies
000155571 7001_ $$aHessmann, Philipp$$b1
000155571 7001_ $$aVogelgsang, Jonathan$$b2
000155571 7001_ $$aSchmidt, Ulrike$$b3
000155571 7001_ $$aRuhleder, Mirjana$$b4
000155571 7001_ $$aSignerski-Krieger, Jörg$$b5
000155571 7001_ $$aRadenbach, Katrin$$b6
000155571 7001_ $$aTrost, Sarah$$b7
000155571 7001_ $$0P:(DE-2719)2814326$$aSchott, Björn H$$b8$$udzne
000155571 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b9$$udzne
000155571 7001_ $$aWolff-Menzler, Claus$$b10
000155571 7001_ $$0P:(DE-2719)9000444$$aBartels, Claudia$$b11$$eCorresponding author$$udzne
000155571 773__ $$0PERI:(DE-600)1459045-1$$a10.1007/s00406-021-01268-6$$n1$$p29-40$$tEuropean archives of psychiatry and clinical neuroscience$$v272$$x1433-8491$$y2022
000155571 8564_ $$uhttps://link.springer.com/article/10.1007%2Fs00406-021-01268-6
000155571 8564_ $$uhttps://pub.dzne.de/record/155571/files/19588.pdf$$yOpenAccess
000155571 8564_ $$uhttps://pub.dzne.de/record/155571/files/19588.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000155571 909CO $$ooai:pub.dzne.de:155571$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000155571 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814326$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000155571 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000155571 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000444$$aExternal Institute$$b11$$kExtern
000155571 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000155571 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000155571 9130_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000155571 9141_ $$y2022
000155571 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-29
000155571 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-29
000155571 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-29
000155571 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000155571 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-29
000155571 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR ARCH PSY CLIN N : 2021$$d2022-11-29
000155571 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000155571 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-02-02$$wger
000155571 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000155571 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-29
000155571 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-29
000155571 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR ARCH PSY CLIN N : 2021$$d2022-11-29
000155571 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000155571 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-29
000155571 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-29$$wger
000155571 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-29
000155571 9201_ $$0I:(DE-2719)1410002$$kAG Fischer 1$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x0
000155571 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lAlzheimer Biomarker and Clinical Study Group$$x1
000155571 980__ $$ajournal
000155571 980__ $$aVDB
000155571 980__ $$aUNRESTRICTED
000155571 980__ $$aI:(DE-2719)1410002
000155571 980__ $$aI:(DE-2719)1410006
000155571 9801_ $$aFullTexts